1. 52P MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager. (December 2022) Authors: Basnet, S.; Santos, J.M.; Quixabeira, D.C.A.; Clubb, J.; Grönberg-Vähä-Koskela, S.; Pakola, S.; Kudling, T.; Heiniö, C.; Havunen, R.; Cervera-Carrascon, V.; Sorsa, S.; Anttila, M.; Kanerva, A.; Hemminki, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗